Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

521
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
521
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Clinical Trials01:16

Clinical Trials

6.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Acoustic analysis of changes in the lens layers after intravitreal dexamethasone implant injection].

Vestnik oftalmologii·2026
Same author

[Clinical case of an inherited retinal disease with late manifestation].

Vestnik oftalmologii·2026
Same author

[Angioid streaks of the retina: diagnosis and treatment].

Vestnik oftalmologii·2026
Same author

[Next-generation pharmaceutically acceptable vehicles for eye drops (preliminary report)].

Vestnik oftalmologii·2026
Same author

[Experimental assessment of mass transfer in the human cornea using cesium ion migration as a model].

Vestnik oftalmologii·2026
Same author

[Monocyte telomere length as a novel biomarker of macular atrophy and response to anti-VEGF therapy in age-related macular degeneration].

Vestnik oftalmologii·2025

Related Experiment Video

Updated: Jul 17, 2025

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.6K

[Faricimab: from research to clinical practice].

Yu N Yusef1,2, M V Budzinskaya1, A A Plyukhova1

  • 1Krasnov Research Institute of Eye Diseases, Moscow, Russia.

Vestnik Oftalmologii
|August 28, 2023
PubMed
Summary
This summary is machine-generated.

Faricimab, a novel anti-angiogenic therapy targeting VEGF-A and Ang-2, demonstrates efficacy in treating retinal diseases. Clinical trials show comparable visual acuity and reduced central retinal thickness, offering a promising treatment option with fewer injections.

Keywords:
age-related macular degenerationanti-VEGF therapydiabetic macular edemafaricimab

More Related Videos

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.9K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.3K

Related Experiment Videos

Last Updated: Jul 17, 2025

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.6K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.9K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.3K

Area of Science:

  • Ophthalmology
  • Vascular Biology
  • Pharmacology

Context:

  • Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are leading causes of vision loss.
  • Current anti-angiogenic therapies require frequent intravitreal injections, posing a treatment burden.
  • Targeting multiple pathways in angiogenesis offers a potential strategy for improved therapeutic outcomes.

Purpose:

  • To evaluate the efficacy and safety of faricimab, a bispecific antibody targeting VEGF-A and Ang-2, in patients with nAMD and DME.
  • To compare faricimab's effectiveness with existing treatments like ranibizumab and aflibercept.
  • To assess the potential of faricimab to reduce treatment burden through less frequent administration.

Summary:

  • Faricimab demonstrated non-inferiority to ranibizumab in maintaining visual acuity and reducing central retinal thickness (CRT) in nAMD patients at extended intervals.
  • In DME patients, faricimab showed dose-dependent improvements in diabetic retinopathy severity and significant reductions in CRT.
  • Clinical trials (TENAYA, LUCERNE, YOSEMITE, RHINE) indicated that faricimab achieved visual acuity gains comparable to aflibercept.
  • Real-world data corroborated clinical trial findings, showing sustained improvements in best-corrected visual acuity (BCVA) and CRT.

Impact:

  • Faricimab offers a dual-pathway anti-angiogenic approach, potentially improving treatment efficacy for retinal vascular diseases.
  • The ability to administer faricimab at longer intervals may reduce the treatment burden for patients with nAMD and DME.
  • These findings support faricimab's potential as a valuable therapeutic option for a broad patient population with retinal conditions.